Exhibitors Search
CBIS
Booth no.
F16/F60
|
Exhibition
|
|KOREA LAB Autumn |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|100 Cheongpa-ro 47-gil, Yongsan-gu, Seoul, Republic of Korea |
|
Tel
|
|+82-2-710-9415 |
|
Exhibits
|
| Q-omics - A Bio-LDM?powered Bio-AI platform that discovers drug targets, biomarkers, and response/resistance mechanisms from proprietary omics data, then validates them with large-scale patient and cell-line evidence. |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup , Digital Health / Medical Device Company |
Exhibitor Information
CBiS is a Bio-AI company that connects omics data to drug-discovery decisions.
Built on more than 20 years of experience in biomedical data and biomarker research, we develop Q-omics, Bio-LDM™ and OmixMind, supported by international patent filings and peer-reviewed publications.
Our platform discovers target, biomarker, mechanism, and resistance hypotheses from proprietary omics data and validates them using large-scale patient and cell-line evidence.
As of July 2026, the public Q-omics SaaS has more than 300 monthly users worldwide.
We welcome partnering discussions with pharmaceutical and biotech companies, hospitals, universities, and public research institutes for PoCs, joint discovery projects, and private deployment.
Built on more than 20 years of experience in biomedical data and biomarker research, we develop Q-omics, Bio-LDM™ and OmixMind, supported by international patent filings and peer-reviewed publications.
Our platform discovers target, biomarker, mechanism, and resistance hypotheses from proprietary omics data and validates them using large-scale patient and cell-line evidence.
As of July 2026, the public Q-omics SaaS has more than 300 monthly users worldwide.
We welcome partnering discussions with pharmaceutical and biotech companies, hospitals, universities, and public research institutes for PoCs, joint discovery projects, and private deployment.
Exhibit Description
At the core of Q-omics is Bio-LDM™, a proprietary ontology-guided biological intelligence engine.
Unlike conventional analyses focused on individual genes, Bio-LDM learns context-specific gene combinations and functional networks from proprietary omics data.
Q-omics MetaDB validates these findings across 1B+ multi-omics data points and 30B+ cross-association results.
NetCrafter interprets mechanism networks, while OmixMind turns user questions and data into customized workflows.
Applications include target and biomarker discovery, drug-response and resistance analysis, synthetic-lethality exploration, and patient-outcome evidence.
Unlike conventional analyses focused on individual genes, Bio-LDM learns context-specific gene combinations and functional networks from proprietary omics data.
Q-omics MetaDB validates these findings across 1B+ multi-omics data points and 30B+ cross-association results.
NetCrafter interprets mechanism networks, while OmixMind turns user questions and data into customized workflows.
Applications include target and biomarker discovery, drug-response and resistance analysis, synthetic-lethality exploration, and patient-outcome evidence.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Q-omics (https://qomics.ai)1) Partners provide a research question and/or omics data. 2) Bio-LDM identifies key gene combinations, functional modules, and network hotspots. 3) Q-omics cross-validates these findings using patient survival and treatment response, tumor-versus-normal profiles, cell-line drug sensitivity, CRISPR/shRNA dependency, proteomic, and immune evidence. 4)Deliverables include prioritized targets, biomarkers, mechanism or resistance hypotheses, evidence matrices, and reproducible workflows. 5) Engagement options include a two-week public-data pilot, a 4~6-week NDA-based PoC, joint discovery projects, and private cloud or on-premises deployment.
KYUNGYON EXHIBITION CORP.
